What is the difference between somatic and germline mutations in Colorectal Cancer

Somatic vs. Germline Mutations in Colorectal Cancer

This is an important distinction that affects how your cancer is treated and whether your family members need screening. Let me explain both clearly.

SOMATIC MUTATIONS: The Cancer's Own Mutations

What they are: Somatic mutations are changes in DNA that occur only in the cancer cells themselves—not in your normal, healthy cells. These mutations develop during your lifetime, usually as cells divide and occasionally make copying errors.

Key characteristics:

• Present ONLY in tumor tissue (not in blood or normal cells)
• Acquired during your lifetime (not inherited)
• Cannot be passed to children
• Specific to YOUR individual cancer

Why they matter for colorectal cancer treatment:

According to the NCCN Guidelines for Colon Cancer, somatic mutations are critical for treatment decisions. Your oncologist will test your tumor for specific somatic mutations including:

• KRAS mutations – If present, you cannot receive EGFR-targeting drugs like cetuximab or panitumumab
• BRAF mutations – Particularly BRAF V600E, which indicates a more aggressive cancer and requires different treatment approaches (often BRAF inhibitors)
• HER2 amplification – Found in about 3% of colorectal cancers overall, but in 5-14% of cases without KRAS/BRAF mutations; opens up targeted therapy options
• POLE/POLD1 mutations – Occur in 2-8% of colorectal cancers and may indicate better response to immunotherapy

---

GERMLINE MUTATIONS: Inherited Mutations

What they are: Germline mutations are changes in DNA that you inherited from one or both parents. These mutations are present in every cell in your body—cancer cells AND normal cells.

Key characteristics:

• Present in ALL your cells (blood, tissue, organs)
• Inherited from parents (can be passed to children)
• Increase lifetime cancer risk
• Often associated with family history of cancer

Why they matter for colorectal cancer:

According to NCCN Guidelines, germline mutations are important for:

1. Lynch Syndrome screening – The most common hereditary colorectal cancer syndrome, caused by mutations in mismatch repair (MMR) genes like MLH1, MSH2, MSH6, or PMS2
2. Family planning – If you have a germline mutation, your siblings and children have a 50% chance of inheriting it
3. Surveillance – Family members may need earlier or more frequent screening
4. Polymerase proofreading-associated polyposis (PPAP) – Caused by germline POLE or POLD1 mutations, predisposing to multiple adenomas and cancers

---

How Testing Works

For somatic mutations:

• Your doctor tests the tumor tissue from your biopsy or surgery
• This tells your oncologist which targeted therapies might work for YOUR specific cancer
• Testing is done in CLIA-certified laboratories using methods like next-generation sequencing (NGS)

For germline mutations:

• Your doctor tests your blood or normal tissue
• This reveals inherited cancer risk
• If found, genetic counseling is recommended
• Family members may benefit from testing and enhanced screening

---

A Practical Example

Imagine two patients both diagnosed with colorectal cancer:

• Patient A has a somatic BRAF V600E mutation in their tumor. This means the cancer cells have this mutation, but their normal cells don't. Their treatment plan will likely include BRAF inhibitors. Their children are NOT at increased risk just because of this mutation.

• Patient B has a germline MLH1 mutation (Lynch syndrome). Every cell in their body carries this mutation. Their cancer developed because of this inherited risk. Their siblings and children each have a 50% chance of inheriting the same mutation and needing enhanced surveillance starting in childhood.

---

Key Takeaway

According to NCCN Guidelines for Colon Cancer, universal testing for mismatch repair (MMR) or microsatellite instability (MSI) is recommended for all newly diagnosed colorectal cancer patients. This helps identify:

• Whether the cancer has somatic MMR defects (affecting treatment)
• Whether Lynch syndrome (germline mutation) might be present (affecting family screening)

---

Questions to Ask Your Oncology Team

1. What somatic mutations were found in my tumor, and how do they affect my treatment options?
2. Do my test results suggest I might have Lynch syndrome or another hereditary cancer syndrome?
3. Should my family members be tested or undergo enhanced screening?
4. Will my somatic mutation status change after treatment, and do I need repeat testing?
5. Should I see a genetic counselor to discuss my results?

---

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.